Implications of early treatment among Medicaid patients with Alzheimer's disease
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective: The objective of this study was to examine the effect of treatment timing on risk of institutionalization of Medicaid patients with Alzheimer's disease (AD) and to estimate the economic implications of earlier diagnosis and treatment initiation. Methods: New Jersey Medicaid claims data (1997–2009) were used retrospectively to study the effect of treatment on time to institutionalization. Observed Medicaid payments were used to calculate savings from delayed institutionalization, adjusting for cost offsets resulting from concurrent changes in use of other medical services. Results: Initiation of existing therapies at earliest symptomatic onset is predicted to delay institutionalization by 91 days, reducing Medicaid costs by $19,108/institutionalized patient. Incorporating an 18.5% cost offset from increased use of other medical services as well as drug costs associated with earlier treatment results in net savings of $12,687/patient. Projected annual Medicaid savings exceed $1 billion. Conclusion: Earlier treatment leads to a small delay in institutionalization among AD patients, resulting in significant costs savings to Medicaid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“The Alzheimer’s Disease Cooperative Study demonstrated that AD patients treated for 2 years with either selegiline or vitamin E experienced delay in AD progression, and that vitamin E delayed institutionalization by approximately 1 year [17].”
BackgroundAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · cited 1×
“However, additional research is needed to validate the application of biomarkers for diagnostic purposes [24,25].”
Background(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
“In itself, the negative predictive value of aPET is highly impactful from diagnostic management [54], financial [55, 56] and patient well-being [57] standpoints.”
BackgroundPre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population
Geldmacher, D. S., Kirson, N. Y., Birnbaum, H. G., Eapen, S., Kantor, E., Cummings, A. K., & Joish, V. N. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0038-9 · Cited by 53
Self-citationDegenhardt, E. K., Witte, M. M., Case, M. G., Yu, P., Henley, D. B., Hochstetler, H. M., D’Souza, D. N., & Trzepacz, P. T. (2016) · Psychosomatics · doi:10.1016/j.psym.2015.12.002 · Cited by 48
Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
Kirson, N. Y., Desai, U., Ristovska, L., Cummings, A. K. G., Birnbaum, H. G., Ye, W., Andrews, J. S., Ball, D., & Kahle-Wrobleski, K. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0303-5 · Cited by 42
“An accurate and timely initial dementia diagnosis may help patients and caregivers better plan for managing the underlying disease and may lower costs to healthcare systems [7, 8].”
BackgroundSelf-citation
Metadata
- Authors
- Geldmacher, D. S., Kirson, N. Y., Birnbaum, H. G., Eapen, S., Kantor, E., Cummings, A. K., & Joish, V. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2013-05-06
- Volume
- 10
- Issue
- 2
- Pages
- 214-224
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1985137371
- Cited by
- 54
- References
- 4
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.